India's First Unique Lab-To-Market Drug To Be Launched by Cadila
This article was originally published in PharmAsia News
India's first new chemical entity to move from laboratory to market, Cadila Healthcare's Lipaglyn (saroglitazar), for treating diabetes, has a launch target after being approved in India as a blockbuster drug expected to reap $1 billion in global annual sales.
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?